重组人生长激素在儿童生长激素缺乏症和特发性矮小症治疗中的临床应用  

Clinical use of rhGH in treatment of growth hormone deficiency and idiopathic short stature in children

作　　者：杨丽萍 宇根于 谢宇飞 Yang Liping;Yu Genyu;Xie Yufei(Department of Pediatrics,Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University,Shanghai 201700,China)

机构地区：[1]复旦大学附属中山医院青浦分院儿科,上海201700

出　　处：《中国药物与临床》2021年第11期1849-1851,共3页Chinese Remedies & Clinics

摘　　要：目的探讨对于儿童生长激素缺乏症(GHD)和特发性矮小症(ISS)患者应用重组人生长激素(rhGH)的治疗效果。方法以2018年6月至2019年11月58例儿童CHD和ISS患者为研究对象,29例GHD患者为GHD组,剩余29例ISS患者为ISS组,2组患者均给予rhGH治疗,比较2组患儿治疗效果。结果在治疗3个月时,ISS组的身高增值(2.8±0.4)cm和生长速度(12.0±2.1)cm/年,显著高于GHD组(2.0±0.5)cm和(9.2±1.8)cm/年;治疗6个月时,ISS组的身高增值和生长速度分别为(5.9±1.3)cm和(11.8±2.7)cm/年,显著高于GHD组(4.8±1.1)cm和(10.0±2.2)cm/年;治疗12个月时,ISS组的身高增值和生长速度分别为(8.8±1.2)cm和(11.6±2.2)cm/年,显著高于GHD组(P<0.05)。经过治疗后,ISS组的促甲状腺激素(TSH)水平和胰岛素样生长因子(IGF)-1水平均明显改善,GHD组的TSH和IGF-1水平也显著升高,差异均有统计学意义(P<0.05)。在不良反应发生率方面,2组比较差异无统计学意义(P>0.05)。结论对于儿童GHD和ISS患儿应用rhGH治疗,具有较为理想的治疗效果,能够促进2种矮小症患儿的身高增长,提高增长速度,改善TSH水平和IGF-1水平,且具有较高的治疗安全性。Objective To investigate the effects of recombinant human growth hormone(rhGH)in children with growth hormone deficiency(GHD)and idiopathic short stature(ISS).Methods Fifty-eight children with GHD or ISS were included as the subjects in the study between June 2018 and November 2019.All patient were divided into the GHD group and ISS group(n=29 each)and treated with rhGH.The therapeutic effects in the two groups were compared.Results At 3 months after the treatment,the height increase and growth rate in the ISS group were significantly higher than those in the GHD group[(2.8±0.4)cm vs(2.0±0.5)cm,(12.0±2.1)cm/year vs(9.2±1.8)cm/year].At 6 months after the treatment,the height increase and growth rate in the ISS group were significantly higher than those in the GHD group[(5.9±1.3)cm vs(4.8±1.1)cm,(11.8±2.7)cm/year vs(10.0±2.2)cm/year].At 12 months after the treatment,the height growth and growth rate in the ISS group were(8.8±1.2)cm and(11.6±2.2)cm/year respectively,which were significantly higher than those in the GHD group(both P<0.05).After treatment,the levels of TSH and IGF-1 in the ISS group significantly improved,and the levels of TSH and IGF-1 in the GHD group also significantly increased,with statistically significant differences(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The rhGH treatment for children with GHD and ISS shows ideal therapeutic effect,It may promote the height growth of children with two kinds of short stature,increase the growth rate,and improve the level of thyroid-stimulating hormone and insulin-like growth factor-1,with high treatment safety.

关 键 词：重组人生长激素 侏儒症 垂体性 

分 类 号：R725.8[医药卫生—儿科]